Bupropion XL — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Depression

• Citalopram
• Fluoxetine
• Sertraline
• Escitalopram

Also listed for Smoking Cessation

• Nicotine gum/lozenges
• Nicotine gum/lozenges 2/4 mg

About Bupropion XL

Bupropion XL is a popular extended-release medication often prescribed for managing major depressive disorder, seasonal affective disorder, and as an aid for smoking cessation. Understanding your treatment is key, and at TheDrugClub, we believe accessing it should be simple and affordable. Discover how our membership can bring you significant savings on essential medications like Bupropion XL.

What is Bupropion XL and What Does It Treat?

Bupropion XL is an extended-release form of the antidepressant bupropion. Unlike some other antidepressants, it belongs to a class known as norepinephrine-dopamine reuptake inhibitors (NDRIs). It's primarily prescribed for several important conditions:

• Major Depressive Disorder (MDD): It helps alleviate symptoms of depression, such as persistent sadness, loss of interest, and fatigue.
• Seasonal Affective Disorder (SAD): For individuals who experience depressive episodes tied to seasonal changes, often during winter months, bupropion XL can be a preventative treatment.
• Smoking Cessation: Under a different brand name (Zyban), bupropion is also used to help people quit smoking by reducing nicotine cravings and withdrawal symptoms.

The "XL" in bupropion XL stands for "extended release," meaning the medication is formulated to release slowly over 24 hours. This allows for once-

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Bupropion XL is approved for (FDA label)

Wellbutrin XL is an aminoketone antidepressant, indicated for: • treatment of major depressive disorder (MDD) ( 1.1 ) • prevention of seasonal affective disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder (MDD) Wellbutrin XL ® (bupropion hydrochloride extended-release) tablets is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).

Source: Read the full FDA label on DailyMed. Label effective date: February 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Bupropion XL (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older [ see Warnings and Precautions (5.1) ]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [ see Warnings and Precautions (5.1) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ( 5.1 ) • Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: a435da9d-f6e8-4ddc-897d-8cd2bf777b21. SPL document ID: 22308f71-fc56-430d-b559-bed47e17a46c. Label effective date: February 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Bupropion XL (FDA label)

Wellbutrin XL extended-release tablets, 150 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets imprinted with “Wellbutrin XL 150” in black ink on one side and the other side plain. Wellbutrin XL extended-release tablets, 300 mg of bupropion hydrochloride, are creamy-white to pale yellow, round tablets imprinted with “Wellbutrin XL 300” in black ink on one side and the other side plain. Extended-release tablets: 150 mg, 300 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: a435da9d-f6e8-4ddc-897d-8cd2bf777b21. SPL document ID: 22308f71-fc56-430d-b559-bed47e17a46c. Label effective date: February 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Bupropion XL (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: • Suicidal thoughts and behaviors in children, adolescents, and young adults [see Warnings and Precautions (5.1) ] • Neuropsychiatric adverse events and suicide risk in smoking cessation treatment [see Warnings and Precautions (5.2) ] • Seizure [see Warnings and Precautions (5.3) ] • Hypertension [see Warnings and Precautions (5.4) ] • Activation of mania or hypomania [see Warnings and Precautions (5.5) ] • Psychosis and other neuropsychiatric events [see Warnings and Precautions (5.6) ] • Angle-Closure Glaucoma [see Warnings and Precautions (5.7) ] • Hypersensitivity reactions [see Warnings and Precautions (5.8) ] Most common adverse reactions are (incidence ≥5%; ≥2× placebo rate): dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: a435da9d-f6e8-4ddc-897d-8cd2bf777b21. SPL document ID: 22308f71-fc56-430d-b559-bed47e17a46c. Label effective date: February 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Bupropion XL (FDA label)

• Wellbutrin XL is contraindicated in patients with seizure disorder. • Wellbutrin XL is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with Wellbutrin XL [ see Warnings and Precautions (5.3) ]. • Wellbutrin XL is contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3) and Drug Interactions (7.3) ] . • The use of MAOIs (intended to treat psychiatric disorders) concomitantly with Wellbutrin XL or within 14 days of discontinuing treatment with Wellbutrin XL is contraindicated. There is an increased risk of hypertensive reactions when Wellbutrin XL is used concomitantly with MAOIs. The use of Wellbutrin XL within 14 days of discontinuing treatment with an MAOI is also contraindicated.

Source: FDA prescribing information (DailyMed). Set ID: a435da9d-f6e8-4ddc-897d-8cd2bf777b21. SPL document ID: 22308f71-fc56-430d-b559-bed47e17a46c. Label effective date: February 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Bupropion XL (FDA label)

• Neuropsychiatric Adverse Events During Smoking Cessation: Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with Wellbutrin XL for the occurrence of such symptoms and instruct them to discontinue Wellbutrin XL and contact a healthcare provider if they experience such adverse events. ( 5.2 ) • Seizure Risk: The risk is dose-related. Can minimize risk by limiting daily dose to 450 mg and gradually increasing the dose. Discontinue if seizure occurs. ( 4 , 5.3 , 7.3 ) • Hypertension: Wellbutrin XL can increase blood pressure.

Source: FDA prescribing information (DailyMed). Set ID: a435da9d-f6e8-4ddc-897d-8cd2bf777b21. SPL document ID: 22308f71-fc56-430d-b559-bed47e17a46c. Label effective date: February 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Bupropion XL (FDA label)

• CYP2B6 inducers: Dose increase may be necessary if coadministered with CYP2B6 inducers (e.g., ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin) based on clinical exposure, but should not exceed the maximum recommended dose. ( 7.1 ) • Drugs metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).

Source: FDA prescribing information (DailyMed). Set ID: a435da9d-f6e8-4ddc-897d-8cd2bf777b21. SPL document ID: 22308f71-fc56-430d-b559-bed47e17a46c. Label effective date: February 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.